The purpose of this study is to compare how well RP2 with nivolumab works compared to ipilimumab with nivolumab in terms of how long patients live and how long they live without their cancer getting worse. During the study, patients will receive their assigned treatment combination over a period of time. Those receiving RP2 will have injections directly into their tumor at certain time points, while all patients will receive infusions of nivolumab through a vein. Patients in the comparison group will also receive ipilimumab infusions. Throughout the study, patients will have regular check-ups and scans to monitor how their cancer responds to treatment and to check for any side effects.

The study will also look at other measures of how well the treatments work, such as how many patients see their tumors shrink, how long any improvement lasts, and how many patients have their disease remain stable. Safety information will be collected to understand what side effects patients may experience with each treatment combination. This study is designed for adult patients who have not previously been treated with medicines called immune checkpoint inhibitors for their cancer.

The study has two groups of patients based on the size and thickness of their tumor. The first group includes patients whose tumors are planned to be treated with plaque brachytherapy, which is a type of radiation therapy where a small radioactive device is placed near the tumor. The second group includes patients whose tumors are larger and would normally require enucleation, which means surgical removal of the eye. Some patients will receive the study medication before their planned treatment, while others will receive the standard treatment without the study medication first. For the first group, the study will measure how many patients experience vision loss and develop macular edema, which is swelling in the central part of the eye that affects vision. For the second group, the study will measure how many patients are able to keep their eye instead of having it removed.

During the study, patients will be monitored regularly with eye examinations and imaging tests to check the size of the tumor and assess vision using standard eye charts. The study will also track any side effects that patients experience and measure changes in the tumor size using ultrasound and eye photographs. The study will follow patients for several years after treatment to see how well the tumor responds and whether the cancer returns or spreads to other parts of the body. The study will also assess the amount of radiation that reaches important structures in the eye when the medication is given before radiation therapy.

The purpose of this study is to investigate whether adding liver-directed radiation therapy to standard treatment can prolong the time before the cancer progresses. Patients will receive the established treatment with tebentafusp (a medication that helps the immune system recognize and attack cancer cells) along with radiation therapy specifically targeting the liver metastases (cancer that has spread to the liver).

Throughout the study, patients will undergo regular assessments to monitor how their cancer responds to treatment, how long the treatment remains effective, and what side effects may occur. The study will also collect blood samples to analyze circulating tumor DNA and immune markers to better understand how the treatment affects the cancer at a molecular level.

Participants in the study will receive tebentafusp and will be monitored over several months to see how their cancer responds to the treatment. The study will look at whether the cancer completely disappears, as well as other outcomes like how long patients live without the cancer coming back. The study will also check for any side effects from the treatment.

Throughout the study, researchers will collect samples from the liver and blood to better understand how tebentafusp works and to identify any markers that might predict how well the treatment will work. This information could help improve future treatments for metastatic uveal melanoma.

Participants in the study will receive either Roginolisib or another treatment selected by their doctor. Roginolisib is taken as a tablet, while other treatments may include medications like Dacarbazine, Opdualag (which contains Nivolumab and Relatlimab), Pembrolizumab, Yervoy (which contains Ipilimumab), or Opdivo (which contains Nivolumab). These treatments are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The study will take place over several months, during which participants will be monitored regularly to assess the effects of the treatment. This includes checking for any changes in the cancer, as well as monitoring overall health and any side effects. The study aims to provide valuable information on the potential benefits of Roginolisib for patients with this challenging form of melanoma.

The purpose of this study is to evaluate how effective the combination of Sitravatinib and Tislelizumab is in treating patients with metastatic uveal melanoma that has spread to the liver. Participants in the study will receive these treatments and will be monitored over a period of time to see how their cancer responds. The study will look at how well the cancer shrinks or stops growing, as well as how long patients live without the cancer getting worse.

Throughout the study, participants will have regular visits to the clinic for treatment and check-ups. These visits will include various tests and examinations to monitor the effects of the treatment. The study aims to provide valuable information on the potential benefits of combining Sitravatinib and Tislelizumab for patients with this specific type of cancer.

The purpose of the study is to understand how safe and tolerable DYP688 is for patients and to see how well it works against these cancers. The study is divided into two phases. In the first phase, researchers will focus on determining the best dose of DYP688 and observing any side effects. In the second phase, they will evaluate how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive DYP688 and will be monitored closely by the research team. This includes regular check-ups and tests to track their health and the cancer’s response to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of DYP688. The study aims to gather important information that could lead to better treatment options for patients with these types of cancers in the future.

Participants in the study will receive either the combination of IDE196 and Crizotinib or another treatment selected by their doctor, which may include medications like Ipilimumab, Nivolumab, Pembrolizumab, or Dacarbazine. The study will be conducted in phases, starting with Phase 2a to find the optimal dose, followed by Phase 2b and Phase 3 to compare the new treatment with existing options. The study will monitor the progression of the disease and overall survival of the participants.

Throughout the study, participants will be closely observed for any side effects and changes in their health. The trial aims to provide valuable information on how well the new treatment works compared to other available therapies. This research is important for developing better treatment options for patients with metastatic uveal melanoma.

The purpose of this study is to evaluate how effective AloCelyvir is in treating patients with metastatic uveal melanoma, especially those with cancer that has spread to the liver. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor how the cancer responds to the treatment over time, using specific criteria to measure changes in the size of the cancer.

Throughout the study, participants will have regular visits and examinations to track their progress. The study aims to understand not only how well the treatment works but also how long patients can live without the cancer getting worse. This information will help determine the potential benefits of AloCelyvir for people with metastatic uveal melanoma.

The purpose of the study is to determine if combining these treatments is safe and effective for patients with liver metastases from uveal melanoma. The treatment plan includes giving medications through intravenous administration, with some medications being delivered directly to the liver through a special procedure. The study consists of two parts – an initial safety evaluation phase followed by a comparison phase between different treatment combinations.

During the study, patients will receive either the liver perfusion treatment alone or liver perfusion treatment combined with both ipilimumab and nivolumab. The medications ipilimumab and nivolumab are types of immunotherapy that work by helping the body’s immune system recognize and attack cancer cells, while melphalan is a chemotherapy drug that directly kills cancer cells.

The study aims to determine if using tebentafusp after initial treatment helps prevent the cancer from returning. Patients who participate will either receive tebentafusp treatment or be placed in an observation group. The treatment period may last up to 6 months, during which patients receiving the medication will get infusions of tebentafusp.

The medication being studied, tebentafusp, is designed specifically for patients whose cancer cells have a particular genetic marker called HLA-A*02:01. During the treatment, doctors will monitor patients for any changes in their condition and keep track of how long patients remain free from cancer recurrence. Regular check-ups and medical tests will be performed to ensure patient safety throughout the study period.

Participants in the study will receive either the combination of IDE196 (Darovasertib) and Crizotinib or a treatment selected by their doctor, which may include medications like Dacarbazine, Pembrolizumab, Ipilimumab, or Nivolumab. The study will last for a period of up to 12 months, during which participants will be monitored regularly to assess the effects of the treatment. The study aims to provide valuable information on the best treatment options for this specific type of cancer.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the progression of the cancer. The study will help determine if the new combination of IDE196 (Darovasertib) and Crizotinib is more effective than the current standard treatments. This research is important for finding better ways to treat metastatic uveal melanoma and improve outcomes for patients with this condition.

The purpose of this study is to evaluate how well patients with uveal melanoma liver metastases respond to these treatments. Participants will be randomly assigned to receive either the combination of PHP with Ipilimumab and Nivolumab or just Ipilimumab and Nivolumab. The study will monitor the progression of the disease, which means checking if the cancer is growing or spreading, and will also look at the overall health and quality of life of the participants.

Throughout the study, participants will receive regular treatments and check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information on whether adding PHP to the treatment plan can improve outcomes for patients with this type of cancer. The trial is expected to continue for several years to gather comprehensive data on the effectiveness and safety of the treatments being tested.

The purpose of this study is to evaluate the effectiveness and safety of Belzupacap Sarotalocan compared to a placebo, which is a sham injection that does not contain the active medication. Participants in the study will receive either the active treatment or the placebo. The study will monitor the participants over a period to assess how the treatment affects the progression of the eye condition.

Throughout the study, participants will undergo regular check-ups to track the condition of their eye and overall health. The study aims to determine how well the treatment works in slowing down or stopping the growth of the lesions or melanoma, as well as ensuring that it is safe for use. The trial is expected to continue until 2027, with recruitment starting in 2024.

Participants in the study will receive Darovasertib in the form of a tablet taken orally. The study will explore the effects of the drug in two different scenarios: before surgery to potentially shrink the tumor and after surgery to prevent the cancer from returning. The study will monitor the occurrence of any side effects and how the drug affects the need for different types of treatment, such as whether surgery can be avoided or if radiation therapy is more effective after taking the drug.

The trial will also assess changes in the size of the tumor and the impact on vision over time. Participants will undergo regular eye examinations to check for any signs of the cancer returning or progressing. The study aims to provide valuable information on the potential benefits of using Darovasertib in treating Uveal Melanoma and improving patient outcomes.

Participants in the study will be randomly assigned to receive either the melatonin treatment or a placebo. The study will be conducted over several years, with regular check-ups to monitor the health and progress of the participants. The main goal is to see how many participants remain free from cancer spread five years after starting the treatment. Additionally, the study will look at overall survival rates, the risk of developing other cancers, and any side effects experienced by participants during the study period.

This trial is an open Phase III study, meaning that both the researchers and participants know which treatment is being administered. The study aims to provide valuable information on whether melatonin can be an effective additional treatment for preventing the spread of uveal melanoma, potentially improving outcomes for patients with this condition.

During the study, participants will receive either the tebentafusp regimen or a treatment selected by their doctor, which may include medications like diphenhydramine, dexamethasone, or paracetamol. Tebentafusp and pembrolizumab are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

The study aims to determine if the tebentafusp regimen can lead to a greater reduction in cancer markers and improve overall survival compared to the other treatments. Participants will be monitored for any side effects and changes in their health throughout the study. The results will help researchers understand the potential benefits of tebentafusp for people with advanced melanoma and guide future treatment options.